Provectus Biopharmaceuticals, Inc.

8-K Director or officer change Jul 1, 2026 8-K Shareholder vote results Jun 22, 2026 8-K Regulation FD disclosure Jun 18, 2026 10-Q Quarter ended 2026-03-31 May 14, 2026 8-K Other events Apr 21, 2026 10-K Fiscal year ended 2025-12-31 Mar 26, 2026 8-K Amended charter or bylaws Feb 2, 2026 10-Q Quarter ended 2025-09-30 Nov 13, 2025 10-Q Quarter ended 2025-06-30 Aug 14, 2025 8-K Shareholder vote results Jun 20, 2025 8-K Regulation FD disclosure Jun 18, 2025 10-K/A Fiscal year ended 2024-12-31 May 16, 2025 10-Q Quarter ended 2025-03-31 May 14, 2025 8-K Changed accountants Apr 16, 2025 10-K Fiscal year ended 2024-12-31 Mar 28, 2025 8-K Entered a material agreement; Took on a direct financial obligation; Unregistered sale of equity Jan 22, 2025 8-K Entered a material agreement Dec 26, 2024 8-K Other events Dec 11, 2024 8-K Director or officer change Dec 5, 2024 8-K Regulation FD disclosure Nov 14, 2024 10-Q Quarter ended 2024-09-30 Nov 12, 2024 8-K Director or officer change Aug 19, 2024 10-Q Quarter ended 2024-06-30 Aug 13, 2024 8-K Entered a material agreement; Took on a direct financial obligation; Unregistered sale of equity Jul 17, 2024 8-K Entered a material agreement; Amended charter or bylaws Jun 25, 2024 8-K Shareholder vote results Jun 21, 2024 8-K Regulation FD disclosure Jun 20, 2024 10-Q Quarter ended 2024-03-31 May 14, 2024 10-K/A Fiscal year ended 2023-12-31 Apr 29, 2024 8-K Director or officer change; Regulation FD disclosure Apr 16, 2024 10-K Fiscal year ended 2023-12-31 Mar 28, 2024 8-K Entered a material agreement; Regulation FD disclosure Mar 27, 2024 8-K Director or officer change Mar 26, 2024 8-K Regulation FD disclosure Feb 22, 2024 8-K Regulation FD disclosure Feb 15, 2024 10-Q Quarter ended 2023-09-30 Nov 14, 2023 10-Q Quarter ended 2023-06-30 Aug 14, 2023 8-K Shareholder vote results Jun 22, 2023 8-K Regulation FD disclosure Jun 21, 2023 10-Q Quarter ended 2023-03-31 May 11, 2023